Edition:
India

Dermira Inc (DERM.OQ)

DERM.OQ on NASDAQ Stock Exchange Global Select Market

7.77USD
15 Feb 2019
Change (% chg)

$0.20 (+2.64%)
Prev Close
$7.57
Open
$7.65
Day's High
$8.08
Day's Low
$7.61
Volume
255,447
Avg. Vol
188,608
52-wk High
$28.35
52-wk Low
$6.00

Latest Key Developments (Source: Significant Developments)

Dermira Inc Says Secured Payer Coverage Of Qbrexza (Glycopyrronium)Cloth
Monday, 7 Jan 2019 

Jan 7 (Reuters) - Dermira Inc ::DERMIRA INC - SECURED PAYER COVERAGE OF QBREXZA (GLYCOPYRRONIUM) CLOTH FOR THE TOPICAL TREATMENT OF PRIMARY AXILLARY HYPERHIDROSIS.  Full Article

Dermira enters into credit facility with Athyrium Capital Management
Tuesday, 4 Dec 2018 

Dec 4 (Reuters) - Dermira Inc ::DERMIRA ENTERS INTO CREDIT FACILITY WITH ATHYRIUM CAPITAL MANAGEMENT.DERMIRA INC - CLOSING OF A $125 MILLION CREDIT FACILITY WITH FUNDS MANAGED BY ATHYRIUM CAPITAL MANAGEMENT, LP.DERMIRA INC - AGREEMENT PROVIDES DERMIRA WITH UP TO $125 MILLION OF BORROWING CAPACITY AVAILABLE IN THREE TRANCHES, EACH BEARING INTEREST AT 10.75%/ANNUM.DERMIRA INC - INITIAL TRANCHE OF $35 MILLION WAS FUNDED AT CLOSING AND AN ADDITIONAL $90 MILLION WILL BE AVAILABLE AT DERMIRA'S OPTION.  Full Article

Dermira Reports Q2 Loss Per Share Of $0.57
Tuesday, 7 Aug 2018 

Aug 6 (Reuters) - Dermira Inc ::DERMIRA REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q2 REVENUE $39.1 MILLION VERSUS I/B/E/S VIEW $39.2 MILLION.QUARTERLY LOSS PER SHARE $0.57.  Full Article

Dermira Reports Q2 Loss Per Share Of $0.57
Tuesday, 7 Aug 2018 

Aug 6 (Reuters) - Dermira Inc ::DERMIRA REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q2 REVENUE $39.1 MILLION VERSUS I/B/E/S VIEW $39.2 MILLION.QUARTERLY LOSS PER SHARE $0.57.  Full Article

Dermira posts Q3 loss $4.30/shr, says FDA accepts NDA for glycopyrronium tosylate
Tuesday, 7 Nov 2017 

Nov 6 (Reuters) - Dermira Inc :Dermira reports third quarter 2017 financial results and announces that FDA accepts new drug application for glycopyrronium tosylate for the treatment of patients with primary axillary hyperhidrosis.Dermira Inc - ‍FDA decision on new drug application for glycopyrronium tosylate expected by June 30, 2018​.Dermira Inc - qtrly net loss per share, basic and diluted $4.30 ‍​.Dermira Inc - updating its financial guidance for full year 2017; now expects collaboration and license revenue of approximately $4.3 million for FY​.  Full Article

Dermira and UCB agree to end collaboration agreement for Cimzia
Tuesday, 7 Nov 2017 

Nov 6 (Reuters) - Dermira Inc :Dermira and UCB agree to end collaboration agreement for Cimzia.Dermira Inc - ‍Dermira to transition development and commercialization responsibility for Cimzia (Certolizumab Pegol) in psoriasis back to UCB​.Dermira Inc - ‍collaboration agreement will terminate on February 15, 2018 and companies anticipate completion of transition by such date​.Dermira Inc - ‍pursuant to collaboration agreement, there are no termination or penalty payments required by either party​.Dermira - for repurchase of all product rights, licenses and intellectual property relating to cimzia, ucb will pay to dermira $11.0 million by Nov 13.  Full Article